Open access
Jul 2026
Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy
The authors design and characterise FR-027, a reversible covalent inhibitor of XPO1 that does not induce XPO1 degradation, demonstrating strong antitumour activity, including in brain tumours, with an improved safety profile in mice.
Janne Van Hauwenhuyse, F. Reniers, L. Persoons et al.
· Nature Communications · 0 citations